Preferences of healthy men for two different endocrine treatment options offered for locally advanced prostate cancer

Current Medical Research and Opinion

Volumn 21, Issue 9, 2005, Pages 1329-1335

  Jenkins, V ^a   Fallowfield, L ^a   Edginton, T ^a   Payne, H ^b   Hamilton, E ^c  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

LHRHa; Locally advanced prostate cancer; NSAA; Patient choice

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

BREAST DISEASE; CANCER GROWTH; CANCER LOCALIZATION; CONFERENCE PAPER; FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; MUSCLE WEAKNESS; PATIENT CARE; PROSTATE CANCER; QUESTIONNAIRE; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; GREAT BRITAIN; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSTATE; PROSTATIC NEOPLASMS; QUESTIONNAIRES;

EID: 25444502383     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X59058     Document Type: Conference Paper

References (28)

1. Cancer Research UK. Scientific Yearbook; 2004
2. Feldman-Stewart D, Brundage MD, Hayter C, et al. What prostate cancer patients should know: variation in professionals' opinions. Radiother Oncol 1998;49:111-23
3. Davison BJ, Parker PA, Goldenberg SL. Patients' preferences for communicating a prostate cancer diagnosis and participating in medical decision-making. Br J Urol Int 2004;93:47-51
4. Templeton H, Coates V. Informational needs of men with prostate cancer on hormonal manipulation therapy. Patient Educ Couns 2003;49:243-56
5. Boccardo F, Barichello M, Battaglia M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 2002;42:481-90
6. Carroll PR, Kantoff PW, Balk SP, et al. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002;60(3 Suppl 1):1-6
7. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000;164:1579-82
8. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median follow-up of 5.4 years. J Urol 2004;172:1865-70
9. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17:2027-38
10. Scholz M, Lamb R. Antiandrogen monotherapy. Available from: www.prostateoncology.com; 2004 [last accessed February 2005]
11. Migliari R, Muscas G, Usai E. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer. J Urol 1992;148:338-41
12. Iversen P, Tammela TL, Vaage S, et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol 2002;42:204-11
13. Tyrrell CJ, Payne H, Tammela TL, et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 2004;60:476-83
14. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004;22:2546-53
15. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181-6
16. Basaria S, Lieb 2nd J, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56:779-86
17. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. New Engl J Med 2005;352:154-64
18. Iversen P. Bicalutamide monotherapy for early stage prostate cancer: an update. J Urol 2003;170:548-52 [discussion S52-4]
19. Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. Br Med J 2004;328:382
20. Fallowfield LJ, Hall A, Maguire P, Baum M, A'Hern RP. Psychological effects of being offered choice of surgery for breast cancer. Br Med J 1994;309:448
21. Fallowfield L, McGurk R, Dixon M. Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. Eur J Cancer 2004;40:2403-10
22. Feldman-Stewart D, Brundage MD, Nickel JC, MacKillop WJ. The information required by patients with early-stage prostate cancer in choosing their treatment. Br J Urol Int 2001;87:218-23
23. Jonker-Pool G, Hoekstra HJ, van Imhoff GW, et al. Male sexuality after cancer treatment - needs for information and support: testicular cancer compared to malignant lymphoma. Patient Educ Couns 2004;52:143-50
24. Detmar SB, Aaronson NK, Wever LD, Muller M, Schornagel JH. How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues. J Clin Oncol 2000;18:3295-301
25. Fallowfield L, Jenkins V. Effective communication skills are the key to good cancer care. Eur J Cancer 1999;35:1592-7
26. Metz R, Namer M, Adenis L, et al. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial. Am J Clin Oncol 1988;11(Suppl 2):S112-4
27. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001;19:72-80
28. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999;54:607-11